| stocks inside;

it’s..

insanity now!

| here you will find really valuable information.

Investing in Space It’s Now! Geospatial and Mobile Infrastructure | Stocks Series .8

“Don’t confuse diplomas with knowledge. I didn’t go to Harvard, but the people who work for me did.”

Elon Musk

You can’t start writing the article about this company without a rational introduction first: People who don’t move, don’t create anything – they just copy. And in this case, whoever moves makes everything happen in the short, medium or long term. Either it creates for now, or it creates something for the future, but it has to move. The purpose of this platform is not only to generate some kind of monetary wealth for those who read, but mainly to generate behavioral, emotional, psychological and philosophical wealth (or not?).

The wisdom still so ignored, abandoned, was replaced by diplomas often ‘delivered’ to individuals who made no effort. Those who were, and still are, considered “crazy”, constitute wisdom and move this world. The rest only copies: and whoever copies always comes later.

The company that I am about to present has a contract signed with SpaceX and is a pioneer in acting in mobile telecommunications space infrastructure. Its shares are at the same value as 2019 due to the current fall in the markets, decreasing the Risk x Return and becoming attractive.

With rational portfolio management, it can be very profitable in the medium/long term.

 FOLLOW ABOUT THIS COMPANY!

Subscribe to get access

SUBSCRIBE NOW to continue reading ALL content!
For only $0.50/month, you can have a great return on theses still unknown.
I need your help to continue with this platform.

Esta imagem possuí um atributo alt vazio; O nome do arquivo é star.png

A Shot In The Moon Or A Shot In The Water | Stocks Series .7

I’ll present a super interesting thesis that involves HIGH Risk x Return. Long-lasting companies that work according to some macro market cycles – whether in the global, regional or local economy. Its Revenues and Profits largely depend on numerous economic, political, social and natural variables.

The share price of a specific industry company can range from $2.50 to $50,000 in the last macro cycle of 2008. The opposite is also extremely acceptable due to its volatility: ranging from $50,000 to $1.80 dollars. So how to profit from these companies?

Which part of the cycle are we in? Follow this THESIS below!

Subscribe to get access

SUBSCRIBE NOW to continue reading ALL content!
For only $0.50/month, you can have a great return on theses still unknown.
I need your help to continue with this platform.

Esta imagem possuí um atributo alt vazio; O nome do arquivo é star.png

Very Cheap Japanese Bank | Series .6 Stocks

Getting rid of the “common paths” of the markets has great benefits. This is because the individual moves away from the herd effect; acquires larger volumes of shares of companies that no one cares about at bargain prices and values ​​its equity when every market sees Value in this Company. There are several reports over the decades, in books obviously, that demonstrate the efficiency of using a heritage policy that distinguishes itself from the vast majority.

Everyone likes to save on a daily basis, but very few people bother to save when entering the markets and buying stocks.

This Japanese Bank has been growing gradually over the past few years, demonstrating strong fundamentals in its balance sheets and consistently giving back to shareholders. Due to being “unknown,” his shares cost only $2.80 and pay $0.17 a year in dividends. Spectacular!

FOLLOW THE DETAILED ANALYSIS AND DISCOVER THIS JAPANESE BANK!

Subscribe to get access

SUBSCRIBE NOW to continue reading ALL content!
For only $3.89 per year, you can have a great return on theses still unknown.
I need your help to continue with this platform.

Esta imagem possuí um atributo alt vazio; O nome do arquivo é star.png

Disruptive Technologies 5G / 6E: $6.9 Billion MARKET IN 2024 | Series of actions .5

In this article I will write about one more Company that has been standing out in the Disruptive Technologies area. The previous companies were, mostly, in the Biotechnology sector, encompassing pharmaceutical companies and very high technology laboratories.

Everything that involves – needs – semiconductors is going through an incredible scarcity: from microchips and microcontrollers, to a large part of electronic components in general. Currently, it is almost unimaginable to think of an essential consumer product that does not have some kind of integrated electronic component: vehicles, cell phones, household equipment, lighting systems, residential, commercial and industrial automated systems, generalized monitoring and control systems , systemic and constant automation, from manufacturing to logistical transport and delivery to the consumer.

Based on this very brief introduction, there is a growing urgency to accelerate the process of evolution in the industry. integrated technologies. The obvious need for global industry and also for the interconnection between people and nations depends on an increasingly agile and efficient system: 5G, 6G and later infrastructure.

Founded in 2014, its stock has cost approximately $4 dollars and has now doubled in value. Your future perspective is amazing: so much for your registered patents; its unique products and services related to the very high frequency; and by the “Target Customers” of its very rare patented pipeline.

FOLLOW THE DETAILED ANALYSIS ON THIS COMPANY

Subscribe to get access

SUBSCRIBE NOW to continue reading ALL content!
For only $3.89 per year, you can have a great return on theses still unknown.

I need your help to continue with this platform.

Esta imagem possuí um atributo alt vazio; O nome do arquivo é star.png

A Giant Entered the Lithium-Ion Market | Stocks Series .4

Continuing the series on Highly profitable and undervalued stocks , I expose an incredible centenary American energetic and her very important points that will, for sure, value your stocks in the medium / long term. There’s no doubt about it: It managed to do something unexpected and innovative in its operating environment this year. It has invested heavily in something that other competitors are unlikely to do at the moment – and when they do, it will be way behind.

There are a lot of bargains and bargains on the market, even with these armed with absolutely leverage. Unlike my analyses: I’m not just based on graphical analysis, media or widely publicized news. I look for strong and consistent points that many have not yet recognized – or have not valued. The goal is to see and acquire companies with Fair Price, Value and Potential , but INVISIBLE!

FOLLOW THE DETAILED ANALYSIS ON THIS COMPANY

Continuing the series on Highly profitable and undervalued stocks , I expose an incredible centenary American energetic and her very important points that will, for sure, value your stocks in the medium / long term. There’s no doubt about it: It managed to do something unexpected and innovative in its operating environment this year. It has invested heavily in something that other competitors are unlikely to do at the moment – and when they do, it will be way behind.

There are a lot of bargains and bargains on the market, even with these armed with absolutely leverage. Unlike my analyses: I’m not just based on graphical analysis, media or widely publicized news. I look for strong and consistent points that many have not yet recognized – or have not valued. The goal is to see and acquire companies with Fair Price, Value and Potential , but INVISIBLE!

FOLLOW THE DETAILED ANALYSIS ON THIS COMPANY

Subscribe to get access

SUBSCRIBE NOW to continue reading ALL content!
For only $3.89 per year, you can have a great return on theses still unknown.

I need your help to continue maintaining this platform.

Esta imagem possuí um atributo alt vazio; O nome do arquivo é star.png

Disruptive Technologies: A TRILLION DOLLAR MARKET AS OF 2025 | Stocks Series .2

THE SECOND COMPANY PRESENTED ON DISRUPTIVE TECHNOLOGIES!
A COMPANY FOUNDED IN 2014 SEEKING ‘IMMORTALITY’.

The principle of the ‘Immortality’ concept has been in development for a few years now, but it is still virtually unknown or purposefully unremarked at the moment because of the great speculation that can be generated: over inflating the assets of these companies.

In this article I will quote the Biopharmaceutical Technology Company which is most advanced in the development of various treatments for autoimmune diseases. His pipeline, in addition to being awesome, meets most of his studies in Phase 2 – of the Three Phases development for new effective treatments. Prevention and Trapping of problems such as: Multiple Sclerosis, Rheumatoid Arthritis, Type 2 Diabetes. Depression inhibitors and the effects of illicit drugs, such as cocaine, are in its pipeline, already in Phase 2.

Did they stop to wonder how many millions of lives these intercepted treatments would change around the world? Millions of people would discover autoimmune diseases in advance: avoiding absurd expenses for the rest of their lives: avoiding absurd spending for the rest of their lives; avoiding an excessive amount of medication; interrupting precious hours of their lives in hospitals and clinics.

FOLLOW MORE TREATMENTS IN DEVELOPMENT AND THEIR EVOLUTION FOR AUTHORIZATION, MARKETING AND PRICE ESTIMATION OF YOUR SHARES WHEN COMPLETING YOUR PIPELINE.

Subscribe to get access

SUBSCRIBE NOW to continue reading ALL content!
For only $3.89 per year, you can have a great return on theses still unknown.

Esta imagem possuí um atributo alt vazio; O nome do arquivo é star.png

Disruptive Technologies: A TRILLION DOLLAR MARKET AS OF 2025 | Stocks Series .1

GET READY, YOU WILL MEET THE FIRST COMPANY!
THIS FIRST ARTICLE WILL TAKE IT UP!

What if you could treat an illness you will have in the future? What if you could treat her two years before she existed?

I’m going to address some totally disruptive tech companies that are still “hidden” and undervalued over the past few years. What do they develop? Advanced treatments for prevention and interception of biological data, delaying the effects of various chronic diseases and enabling the patient to act directly against something that already has a predisposition. Your later ability?

A MARKET FROM

TRILLION DOLLARS

FROM 2025

Subscribe to get access

SUBSCRIBE NOW to continue reading, not just this one, but ALL the contents!
For only $3.89 per year, you can have a great return on theses still unknown.

Esta imagem possuí um atributo alt vazio; O nome do arquivo é star.png

URANIUM!

The famous Uranium thesis and future price perspective according to demand.

Follow and think about it often on Uranium since 2019, when we confirmed that the numbers will finally be showing all these years. Reflections, beliefs and studies on the concept of the future of the United States, in theory, are simple, or if it is really hard to find, you will find valid and valuable information for a more assertive subject about the most racist.

I have always reflected on countless and absurd subjects during the course of my blessed days, whether waking up or sleeping: I just think and think. Soon, given the monstrous increase in energy demand, I began to investigate more deeply into the commonly used energy matrices and whether they really support the demanded load.

Note: I refer to “load” in the following sense:

1. A single lit lamp consumes a certain charge;

2. A cell phone charger also consumes another charge.

According to long-term expectations, energy matrices in high use (hydro, fossil, solar and wind) will not support the excessive and practically instantaneous demand that is rapidly moving towards us. It is observed, for example, developed nations and even the Asian and European continent massively abolishing the use of combustion-powered vehicles due to the catastrophic global thermal effect.

Subscribe to get access

Do you want to continue knowing the future of Uranium? How far can the price go?

Subscribe now! Only $3.89/year and release all content.

BREAK NEWS: 2021 American Urological Association Results

In the last post I opened my idea about the biotechnology company that develops the latest generation in the treatment of urethral and kidney cancer. Today, the same company released its latest results on its treatments. BOOM!!

Subscribe to get access

SUBSCRIBE NOW to continue reading, not just this one, but ALL the contents!
For only $3.89 per year, you can have a great return on theses still unknown.

Unknown? Leading Biopharmaceutical Innovation – Special Cancer and Urological Diseases

76% devaluation since 2018.

“I appreciate this! Companies that have become ‘forgotten’ over a period of time for lack of mainstream media emphasis; also nearly forgotten by analysts and the widespread ability of popular digital influencers to repeat the same things over and over again – always in the same direction I seek on this platform exactly the opposite: to expose what is still hidden from the eyes of the majority.”

With a devaluation of 76% since May 2018, this company has already grown absurdly in its pipeline of innovative treatments against special cancers and urological diseases, including one of the treatments already approved by the FDA (Food and Drug Administration is a federal agency of the Department Health and Human Services Department) and being widely marketed. The great differential in its innovative treatments stands out for its non-invasive feature (WITHOUT SURGERY), especially in the urological system.

The company, founded in 2004, has a market value of approximately $200 million dollars, but with just the first treatment approved this year, it has already secured revenue of $13 million in the last quarter. Therefore, possibly, its stock values ​​tend to have a STRONG valuation in the medium and long term.

Keep reading to find out what THIS company IS and about the possible return OF YOUR ACTIONS.

Subscribe to get access

SUBSCRIBE NOW to continue reading, not just this one, but ALL the contents!
For only $3.89 per year, you can have a great return on theses still unknown.

Subscribe to get access

SUBSCRIBE NOW to continue reading, not just this one, but ALL the contents!
For only $3.89 per year, you can have a great return on theses still unknown.

Last Generation In Cancer Treatment

I start my studies showing the subscriber the first company that lately I am paying a lot of attention due to its extremely effective development against several different types of cancer. The company was founded in 2014 to develop state-of-the-art therapies to serve cancer patients through specialized knowledge of biological pathways critical to the immunosuppressive tumor microenvironment.

With the company’s IPO in 2018, where each quota cost approximately $13.80, today, September 7, is costing $6.39. Since its IPO, its shares have depreciated 54%. But don’t be fooled by this “devaluation” – I explain later. In this period since its listing on Nasdaq, its shares have already cost only $1.67 (because of the misguided behavioral desperation of individuals operating in the markets).

I find very interesting the exponential growth capacity that this Company still has ahead: Its Price/Earnings is extremely low and devalued compared to competitors who are slowly crawling in cancer treatments.

According to my studies and data collected by analysts, their shares should already be worth approximately US$15.00, but their FAIR PRICE is.Charts below.

Subscribe to get access

SUBSCRIBE NOW to continue reading, not just this one, but ALL the contents!
For only $3.89 per year, you can have a great return on theses still unknown.

Unknown That Can Enrich You VERY MUCH in the Medium-Long Term.

Oncology Highlights: Second Quarter

Giving another emphasis on the previous post, I should mention as a general knowledge about the highlights of the Company cited. It is also worth mentioning that due to the costs of the platform domain, it is necessary to limit the content only to members who subscribe to this platform. The amount will be set at $1.99/year so that costs are covered and I can continue working on theses and investment studies that are still unknown, or prioritizing important information about the markets that the reader will rarely find.

According to the effective development of cancer cell treatments and the ABSOLUTE ADVANCEMENT of therapeutic programs far beyond competing institutions, I believe that the market will soon recognize the real value of this Company.

Check below the future prospects and the average value of the shares that may arrive very soon.

HIGHLIGHTS OF AUGUST/2021..

Subscribe to get access

SUBSCRIBE NOW to continue reading, not just this one, but ALL the contents!
For only $3.89 per year, you can have a great return on theses still unknown.